ストックスクリーナーアプリを入手
151.40
0.19%
0.28
アフターアワーズ：
151.41
0.010
+0.01%
前日終値:
$151.12
開ける：
$150.58
24時間の取引高:
6.96M
Relative Volume:
0.96
時価総額：
$187.84B
収益：
$29.42B
当期純損益:
$8.51B
株価収益率:
22.33
EPS:
6.7801
ネットキャッシュフロー:
$10.02B
1週間 パフォーマンス:
-2.31%
1か月 パフォーマンス:
+21.96%
6か月 パフォーマンス:
+27.52%
1年 パフォーマンス:
+37.60%
1日の値動き範囲:
$150.09
$153.25
1週間の範囲:
$150.09
$156.01
52週間の値動き範囲:
$93.37
$157.29
Gilead Sciences Inc Stock (GILD) Company Profile
Compare GILD vs LLY, JNJ, ABBV, AZN, NVS
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
151.40 | 187.49B | 29.42B | 8.51B | 10.02B | 6.7801 |
|
LLY
Lilly Eli Co
|
1,009.52 | 965.26B | 65.18B | 20.64B | 5.96B | 22.59 |
|
JNJ
Johnson Johnson
|
242.49 | 595.03B | 94.19B | 26.80B | 19.70B | 11.05 |
|
ABBV
Abbvie Inc
|
224.81 | 396.51B | 61.16B | 4.20B | 19.68B | 2.3671 |
|
AZN
Astrazeneca Plc
|
204.20 | 323.42B | 58.80B | 10.24B | 8.98B | 3.2788 |
|
NVS
Novartis Ag Adr
|
162.67 | 312.78B | 54.72B | 14.02B | 15.32B | 7.1855 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-02-20 | 開始されました | Barclays | Equal Weight |
| 2026-02-11 | 繰り返されました | Needham | Buy |
| 2026-01-07 | 再開されました | UBS | Buy |
| 2025-11-24 | 再開されました | Truist | Buy |
| 2025-11-13 | 開始されました | Scotiabank | Sector Outperform |
| 2025-08-19 | アップグレード | Daiwa Securities | Neutral → Outperform |
| 2025-08-08 | アップグレード | Truist | Hold → Buy |
| 2025-07-25 | アップグレード | Needham | Hold → Buy |
| 2025-04-22 | 再開されました | Cantor Fitzgerald | Overweight |
| 2025-03-04 | 繰り返されました | Oppenheimer | Outperform |
| 2025-02-18 | アップグレード | Deutsche Bank | Hold → Buy |
| 2025-02-13 | アップグレード | DZ Bank | Hold → Buy |
| 2025-01-10 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | 再開されました | BofA Securities | Buy |
| 2024-11-15 | 開始されました | Wolfe Research | Outperform |
| 2024-11-14 | 開始されました | Citigroup | Buy |
| 2024-11-08 | ダウングレード | Maxim Group | Buy → Hold |
| 2024-10-21 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2024-10-17 | 開始されました | Bernstein | Outperform |
| 2024-10-07 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2024-07-08 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2024-05-01 | 繰り返されました | Maxim Group | Buy |
| 2024-04-24 | アップグレード | HSBC Securities | Reduce → Hold |
| 2024-02-22 | ダウングレード | Truist | Buy → Hold |
| 2023-11-09 | 開始されました | Deutsche Bank | Hold |
| 2023-09-08 | アップグレード | BofA Securities | Neutral → Buy |
| 2023-09-06 | 開始されました | HSBC Securities | Reduce |
| 2023-07-24 | 繰り返されました | Barclays | Equal Weight |
| 2023-05-16 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-28 | 再開されました | Piper Sandler | Overweight |
| 2023-01-03 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-12-13 | 再開されました | BofA Securities | Neutral |
| 2022-12-09 | ダウングレード | DZ Bank | Buy → Hold |
| 2022-10-31 | アップグレード | Barclays | Underweight → Equal Weight |
| 2022-10-28 | 繰り返されました | BMO Capital Markets | Market Perform |
| 2022-10-28 | 繰り返されました | Cowen | Outperform |
| 2022-10-28 | 繰り返されました | JP Morgan | Overweight |
| 2022-10-28 | 繰り返されました | Jefferies | Buy |
| 2022-10-28 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2022-10-28 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2022-10-28 | アップグレード | Truist | Hold → Buy |
| 2022-10-28 | 繰り返されました | Wells Fargo | Equal Weight |
| 2022-10-04 | アップグレード | JP Morgan | Neutral → Overweight |
| 2022-07-13 | 開始されました | Cantor Fitzgerald | Neutral |
| 2022-05-23 | 開始されました | SVB Leerink | Mkt Perform |
| 2022-02-28 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-02 | 繰り返されました | BMO Capital Markets | Outperform |
| 2022-02-02 | 繰り返されました | BofA Securities | Neutral |
| 2022-02-02 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2022-02-02 | 繰り返されました | Truist | Hold |
| 2022-02-02 | 繰り返されました | Wells Fargo | Equal Weight |
| 2022-01-28 | アップグレード | Argus | Hold → Buy |
| 2022-01-06 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-09 | 再開されました | Wells Fargo | Equal Weight |
| 2021-12-06 | 開始されました | Goldman | Neutral |
| 2021-11-19 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2021-11-19 | 再開されました | Piper Sandler | Neutral |
| 2021-10-20 | 再開されました | Cowen | Outperform |
| 2021-07-30 | 繰り返されました | BMO Capital Markets | Market Perform |
| 2021-07-30 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2021-04-01 | アップグレード | Bernstein | Mkt Perform → Outperform |
| 2021-03-30 | アップグレード | Redburn | Neutral → Buy |
| 2021-01-19 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2021-01-04 | アップグレード | Guggenheim | Neutral → Buy |
| 2020-11-03 | 再開されました | Morgan Stanley | Equal-Weight |
| 2020-10-28 | 開始されました | UBS | Neutral |
| 2020-09-30 | 再開されました | Jefferies | Buy |
| 2020-09-15 | アップグレード | Maxim Group | Hold → Buy |
| 2020-07-31 | 繰り返されました | Credit Suisse | Neutral |
| 2020-07-31 | 繰り返されました | Morgan Stanley | Equal-Weight |
| 2020-07-31 | 繰り返されました | Piper Sandler | Overweight |
| 2020-07-31 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2020-07-31 | 繰り返されました | SunTrust | Hold |
| 2020-07-31 | 繰り返されました | Wells Fargo | Equal Weight |
| 2020-07-20 | アップグレード | Credit Suisse | Underperform → Neutral |
| 2020-06-03 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2020-05-26 | アップグレード | SunTrust | Sell → Hold |
| 2020-05-01 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-05-01 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2020-05-01 | ダウングレード | SunTrust | Hold → Sell |
| 2020-04-27 | ダウングレード | UBS | Buy → Neutral |
| 2020-04-20 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2020-04-20 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | ダウングレード | CFRA | Hold → Sell |
すべてを表示
Gilead Sciences Inc (GILD) 最新ニュース
Lansforsakringar Fondforvaltning AB publ Grows Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat
Stevens Capital Management LP Invests $5.11 Million in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences (NASDAQ:GILD) Rating Increased to Hold at Barclays - MarketBeat
Empirical Financial Services LLC d.b.a. Empirical Wealth Management Purchases 26,882 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Barclays Initiates Coverage of Gilead Sciences (GILD) with Equal-Weight Recommendation - Nasdaq
Time To Take Profits On Gilead Sciences (Rating Downgrade) (NASDAQ:GILD) - Seeking Alpha
Where Gilead Sciences Stands With Analysts - Benzinga
Argus Issues Positive Forecast for Gilead Sciences (NASDAQ:GILD) Stock Price - MarketBeat
Barclays initiates Gilead Sciences stock coverage at Equalweight - Investing.com
Barclays Begins Coverage on Gilead Sciences (NASDAQ:GILD) - MarketBeat
Stem Cell and Regenerative Therapy Markets, 2022-2025 & - GlobeNewswire
Stem Cell and Regenerative Therapy Markets, 2022-2025 & Forecast to 2030 Featuring Profiles of Leading CompaniesGilead Sciences, Novartis, Bristol-Myers Squibb, Organogenesis, MiMedx Group and More - Yahoo Finance
China Universal Asset Management Co. Ltd. Increases Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
PatientView Ranks Gilead “Best” at ESG - CSRwire
Peering Into Gilead Sciences Inc's Recent Short Interest - Benzinga
What Do Analysts Have to Say About Gilead Sciences (GILD) Post Earnings? - Finviz
Mizuho Increases Gilead Sciences (NASDAQ:GILD) Price Target to $170.00 - MarketBeat
Is Most-Watched Stock Gilead Sciences, Inc. (GILD) Worth Betting on Now? - Yahoo Finance
Gilead Sciences, Inc. $GILD Shares Purchased by NewEdge Wealth LLC - MarketBeat
Hodges Capital Management Inc. Takes Position in Gilead Sciences, Inc. $GILD - MarketBeat
Insider Sell: Andrew Dickinson Sells 3,000 Shares of Gilead Scie - GuruFocus
Johanna Mercier Sells 28,000 Shares of Gilead Sciences (NASDAQ:GILD) Stock - MarketBeat
Insider Selling: Gilead Sciences (NASDAQ:GILD) CFO Sells 3,000 Shares of Stock - MarketBeat
Gilead-Genhouse's $1.5B+ deal boosts synthetic lethality push - BioWorld MedTech
Gilead Sciences to Present New HIV Treatment and Prevention Data at CROI 2026 - National Today
UBS raises Gilead Sciences stock price target on HIV pipeline data - Investing.com
Mizuho Securities Lifts Gilead Sciences Price Target to $170 From $140, Maintains Outperform Rating - marketscreener.com
Gilead Sciences (NASDAQ:GILD) Price Target Raised to $170.00 at Rothschild & Co Redburn - MarketBeat
[Press release] Gilead to present new HIV treatment and prevention data at CROI 2026, with a focus on expanding options - European AIDS Treatment Group
Gilead Sciences, China's Qinhao Pharmaceutical Sign Global Deal for Tumor Therapy Candidate - marketscreener.com
Gilead Sciences (GILD) Secures Rights to Genhouse Bio's Cancer T - GuruFocus
Gilead to Present New HIV Treatment and Prevention Data at CROI 2026, With a Focus on Expanding Opti - PharmiWeb.com
Gilead’s HIV Advances And Yescarta Label Shift Refocus Investment Thesis - Yahoo Finance
Rothschild & Co Redburn Adjusts Gilead Sciences PT to $170 From $159, Maintains Buy Rating - marketscreener.com
Gilead to Present New HIV Treatment and Prevention Data at CROI 2026, With a Focus on Expanding Options - Business Wire
5 Insightful Analyst Questions From Gilead Sciences's Q4 Earnings Call - Finviz
NEOS Investment Management LLC Has $64.06 Million Stake in Gilead Sciences, Inc. $GILD - MarketBeat
M&G PLC Has $10.82 Million Stake in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Shares Sold by Skandinaviska Enskilda Banken AB publ - MarketBeat
Fifth Third Bancorp Has $43.69 Million Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Investors heavily search Gilead Sciences, Inc. (GILD): Here is what you need to know - MSN
5 Insightful Analyst Questions From Gilead Sciences’s Q4 Earnings Call - Yahoo Finance
Gilead Sciences, Inc. (GILD): Investor Outlook on Robust Growth and Strategic Collaborations - DirectorsTalk Interviews
Zions Bancorporation National Association UT Has $4.46 Million Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Vanguard Group Inc. Has $13.21 Billion Stake in Gilead Sciences, Inc. $GILD - MarketBeat
Todd Asset Management LLC Sells 22,499 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead strikes $1.5 billion cancer pact with Genhouse Bio - The Pharma Letter
Gilead Sciences, Inc. $GILD Shares Purchased by Public Sector Pension Investment Board - MarketBeat
Analyst recommendations: Eagle Materials, Coinbase Global, Gilead Sciences, Royal Gold… - marketscreener.com
Shell Asset Management Co. Sells 54,965 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
State of New Jersey Common Pension Fund D Buys 16,160 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences Inc (GILD) 財務データ
収益
当期純利益
現金流量
EPS
Gilead Sciences Inc (GILD) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Mercier Johanna | Chief Comm & Corp Aff Officer |
Feb 17 '26 |
Sale |
154.44 |
28,000 |
4,324,228 |
120,288 |
| Dickinson Andrew D | Chief Financial Officer |
Feb 17 '26 |
Sale |
154.43 |
3,000 |
463,290 |
167,779 |
0.20%
0.33%
大文字化:
|
ボリューム (24 時間):